Current Research
|
Title |
Sponsor |
IRB KC Number |
Status |
|
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 versus Placebo for the Prevention of Episodic Cluster Headache (Protocol TV48125-CNS-30056) PI: David B. Watson MD |
Teva Branded Pharmaceutical Products R & D CRO: NCGS |
1611350588 |
Open to Enrollment |
|
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 versus Placebo for the Prevention of Chronic Cluster Headache (Protocol TV48125-CNS-30057) PI: David B. Watson MD |
Teva Branded Pharmaceutical Products R & D CRO: NCGS |
1611350853 |
Open to Enrollment |
|
A Multicenter, Double-Blind, Double-Dummy Study to Explore the Long-Term Safety of TEV-48125 for the Prevention of Cluster Headache (Protocol TV48125-CNS-30058) PI: David B. Watson MD |
Teva Branded Pharmaceutical Products R & D CRO: NCGS |
1611351260 |
Open to Enrollment |
|
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine (Protocol TV48125-CNS-30049) PI: David B. Watson MD |
Teva Branded Pharmaceutical Products R & D CRO: NCGS |
1604085070 |
Closed to Enrollment Sponsor in process of closing out sites |
|
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine (Protocol TV48125-CNS-30050) PI: David B. Watson MD |
Teva Branded Pharmaceutical Products R & D CRO: NCGS |
1604086024 |
Closed to Enrollment Sponsor in process of closing out sites |
|
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine (Protocol TV48125-CNS-30051) PI: David B. Watson MD |
Teva Branded Pharmaceutical Products R & D CRO: NCGS |
1604086056 |
Closed to Enrollment Sponsor in process of closing out sites |
|
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single Attack Study To Evaluate The Efficacy, Safety, and Tolerability of Oral Ubrogepant In The Acute Treatment of Migraine (Protocol UBR-MD-02) PI: David B. Watson MD |
Allergan Sales, LLC |
1608249960 |
Open to Enrollment |
|
A Multicenter, Randomized, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Ubrogepant In The Acute Treatment of Migraine With Or Without Aura (Protocol UBR-MD-04) PI: David B. Watson MD |
Allergan Sales, LLC |
1608250247 |
Closed to Enrollment |
|
Title |
Sponsor |
IRB KC Number |
Status |
|
A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS) (Protocol CY 4031) PI: Shumaila Sultan MD |
Cytokinetics, Inc. CRO: Parexel |
1505698254/1606162563 |
Closed to Enrollment Patients in active long-term follow-up |
|
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY4031) (Protocol CY 4033) PI: Shumaila Sultan MD |
Cytokinetics, Inc. CRO: Parexel |
1609296113 |
Open to Enrollment |
|
A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of CK-2127107 in Patients with Amyotrophic Lateral Sclerosis (ALS) (Protocol CY 5022) PI: Shumaila Sultan MD |
Cytokinetics, Inc. CRO: Parexel |
IRB Pending/ Submitted |
|
|
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Episodic Cluster Headache (Protocol I5Q-MC-CGAL) PI: David B. Watson MD |
Eli Lilly and Company CRO: Quintiles |
1503605634 |
Open to Enrollment |
|
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 with a Long-Term Open-Label Extension in Patients with Chronic Cluster Headache (Protocol I5Q-MC-CGAM) PI: David B. Watson MD |
Eli Lilly and Company CRO: Quintiles |
1505677968 |
Open to Enrollment |
|
A Phase 3b Multicenter, Single-Arm, Open-Label Safety Study of LY2951742 (galcanezumab) in Patients with Episodic or Chronic Cluster Headache (Protocol I5Q-MC-CGAR) PI: David B. Watson MD |
Eli Lilly and Company CRO: Quintiles |
IRB Pending/Not Submitted Awaiting sponsor approval of consents |
|
|
Controlled Trial of 3, 4 Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (LEMS) PI: Shumaila Sultan MD |
Sponsor-Investigator (WVU holds IND) Jacobus Pharmaceuticals |
1402212067 |
Open to Enrollment Patients in Long-term follow-up |
|
A Phase 3 randomized, multicenter, multinational, double-blinded study comparing the efficacy and safety of repeated biweekly infusions of neoGAA (GZ402666) and alglucosidase alfa in treatment-naïve patients with late onset Pompe disease (Protocol EFC14028) PI: Cheryl Smith MD, PhD |
Sanofi-Genzyme |
IRB Pending/ Submitted |
|
|
A Pilot Study of Muscle Ultrasound Measures As Biomarkers of Upper Motor Neuron Function PI: Shumaila Sultan MD |
Investigator-initiated |
1703516653 |
Open to Enrollment |
|
Neuroelectrical Stimulation in Guillian Barre Syndrome PI: Cheryl Smith MD, PhD |
Investigator-initiated |
1703497861 |
IRB Pending |
|
Phase 2 Study in Subjects with Persistent Posttraumatic Headache (PPHT): PI: Umer Najib MD |
Teva Branded Pharmaceutical Products R & D CRO: ICON |
CDA signed/Start-up |
|
|
gammaCore® (non-invasive vagus nerve stimulator) for the acute treatment of pain associated with episodic cluster headaches in adult patients: A Non-Research Registry PI: Kristina Lopez MD |
Electrocore, LLC |
Start-up Phase |
|
|
Multi-Center, Concurrent-Controlled, On-Label Study of the NeuRx Diaphragm Pacing System (DPS) in Participants with Amyotrophic Lateral Sclerosis (ALS) PARADIGM PI: Divisha Raheja MD |
Synapse |
Start-up Phase |